Lupus & antiphospholipid syndrome
Lupus nephritis at systemic lupus erythematosus onset and kidney outcomes in a Latin American biopsy-proven cohort
Authors' conclusion
LNSO was not independently associated with kidney or survival outcomes.
Study context
- Population
- Adults (≥18 years) with biopsy-proven lupus nephritis (LN), tertiary centers in Colombia (2011–2024)median follow-up 5.3 years
- Participants
- 428 adults
- Exposure
- LN at systemic lupus erythematosus (SLE) onset vs LN occurring later
- LNSOn = 281
- non-LNSOn = 147reference
- Outcome
- ESKD: sustained eGFR <15 mL/min/1.73 m² for ≥3 months, chronic dialysis, or kidney transplantation
Methodological detailsmulticentre (tertiary centers), cause-specific Cox and Fine-Gray models, 180-day landmark analysis
- Multicentre (tertiary centers)
- Cause-specific Cox and Fine-Gray models
- 180-day landmark analysis
Main finding
As reported in the abstract
ESKD
LNSO vs non-LNSOEstimate (95% CI)
ESKD
aHR 0.87(0.48–1.60)
Competing-risk model
sHR 0.85(0.19–3.84)
- End-stage kidney disease (ESKD) overall
- 72 patients (16.8%)
Observational data: associations, not effects.
Secondary outcomes
Composite of ESKD, death, or doubling of creatinine
- Occurred in 156 patients; not associated with LNSO
Predictors of ESKD
- Lower baseline eGFR, higher NIH chronicity index, and higher non-renal damage associated with ESKD
No remission at 6 months (180-day landmark analysis)
- Strongly predicted adverse outcomes
Original publication
Lupus nephritis at systemic lupus erythematosus onset and kidney outcomes in a Latin American biopsy-proven cohort. Lupus. Published 27 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →